Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib for Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors in Pediatric Participants
NCT03934372Phase 2Recruiting
- Sponsor
- Incyte
- Start
- Jan 2020
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of ponatinib in leukemia, lymphoma, solid tumor, sponsored by Incyte. Started Jan 2020; status: recruiting.
02
Drugs
ponatinib
03
Conditions
leukemialymphomasolid tumor
Beyond the preview
Go deeper on NCT03934372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934372.